valzap 80mg potahovaná tableta
zentiva, k.s., praha array - 13182 valsartan - potahovaná tableta - 80mg - valsartan
vapress 160mg potahovaná tableta
medochemie ltd., limassol array - 13182 valsartan - potahovaná tableta - 160mg - valsartan
vapress 80mg potahovaná tableta
medochemie ltd., limassol array - 13182 valsartan - potahovaná tableta - 80mg - valsartan
wamlox 10mg/160mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan - potahovaná tableta - 10mg/160mg - valsartan a amlodipin
wamlox 5mg/160mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan - potahovaná tableta - 5mg/160mg - valsartan a amlodipin
wamlox 5mg/80mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan - potahovaná tableta - 5mg/80mg - valsartan a amlodipin
tonarssa 2,85mg/2,5mg tableta
krka, d.d., novo mesto, novo mesto array - 13049 perindopril-erbumin; 12990 amlodipin-besilÁt - tableta - 2,85mg/2,5mg - perindopril a amlodipin
tonarssa 5,7mg/5mg tableta
krka, d.d., novo mesto, novo mesto array - 13049 perindopril-erbumin; 12990 amlodipin-besilÁt - tableta - 5,7mg/5mg - perindopril a amlodipin
edarbi
takeda pharma a/s - azilsartan medoxomil - hypertenze - agens působící na systém renin-angiotenzin - přípravek edarbi je určen k léčbě esenciální hypertenze u dospělých.
eucreas
novartis europharm limited - vildagliptin, metformin hydrochloridu - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.